Ligand Pharmaceuticals Incorporated (LGND : NASDAQ)
Common Stock
$298.41
USD
+8.34 (2.88%)
Last updated: 2026-09-23
Follow LGND
LGND
Ligand Pharmaceuticals Incorporated
WealthAwesomePerformance
1 Day
+2.88%
1 Week
+8.43%
1 Month
+6.51%
YTD
+13.40%
Key Statistics
Market Cap
$5.95B
52W High
$326.63
52W Low
$166.10
P/E Ratio
30.71
50 Day MA
$291.18
200 Day MA
$236.49
Beta
0.98
Dividend Yield
-
Advertisement
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 9/23/2026 | $300.44 | $302.44 | $296.08 | $298.41 | $298.41 | 242,000 |
| 9/21/2026 | $283.67 | $290.51 | $282.45 | $290.07 | $290.07 | 237,400 |
| 9/18/2026 | $285.63 | $285.64 | $280.49 | $283.49 | $283.49 | 372,800 |
| 9/17/2026 | $279.51 | $285.51 | $273.10 | $284.70 | $284.70 | 248,800 |
| 9/16/2026 | $277.97 | $278.74 | $271.22 | $275.20 | $275.20 | 299,000 |
| 9/15/2026 | $280.53 | $280.53 | $270.77 | $276.98 | $276.98 | 180,200 |
| 9/14/2026 | $284.93 | $287.14 | $280.12 | $280.65 | $280.65 | 158,800 |
| 9/11/2026 | $291.48 | $294.00 | $283.77 | $284.47 | $284.47 | 261,200 |
| 9/10/2026 | $285.00 | $291.26 | $283.04 | $289.25 | $289.25 | 146,600 |
| 9/9/2026 | $288.03 | $291.82 | $285.48 | $288.05 | $288.05 | 310,000 |
Analyst Price Targets
Based on 7 analysts covering LGND · as of Sep 17, 2026
Wall Street analysts forecast LGND stock price to rise 14.9% over the next 12 months.
Consensus
Strong Buy4.57 / 5.00
Avg. Target
US$342.82
+14.9% Upside
Current Price
US$298.41
Last close
Analyst Breakdown (7 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on LGND's historical volatility
30-Day Vol
25.0%
Annualized
90-Day Vol
34.0%
Annualized
Trend (90d)
-7.2%
Annualized drift
90d Mean
US$290.81
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | US$295.85 | US$271.44 – US$322.47 |
| 60 trading days | US$293.32 | US$259.68 – US$331.32 |
| 90 trading days | US$290.81 | US$250.50 – US$337.59 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma. The company also provides Teriparatide injection product for osteoporosis; RYLAZE, a recombinant erwinia asparaginase for acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes in adults and children aged 8 years and older with Stage 2 T1D; and VAXNEUVANCE for the prevention of invasive disease caused by streptococcus pneumoniae serotypes. In addition, it offers Duavee for menopause; Frovatriptan to treat Neurology; FYCOMPA and SESQUIENT for CNS; MEKINIST for cardiology; Nexterone, a captisol-enabled formulation of amiodarone; VEKLURY, an antiviral treatment for COVID-19; and Viviant for osteoporosis. Further, the company develops ACLX-002, Ciforadenant, UGN-301, Viright, MB07133, BOT/BAL, and Lasofoxifene for oncology; Ensifentrine for respiratory disease; QTORIN for rare disease; Sparsentan for kidney disease; VK2809 for hepatology; ANEB-001 for acute cannabinoid intoxication; Reproxalap for opthamology; VK0214 for Rare Disease; and VK5211 for musculoskeletal disorder. The company was incorporated in 1987 and is based in Jupiter, Florida.
Financials
- Revenue (TTM)
- $290.54M
- EBITDA
- $133.01M
- Profit Margin
- 67.88%
- ROE (TTM)
- 21.96%
- EPS (Diluted)
- 9.72
- Book Value
- 48.57
Classification
- Sector
- Health Care
- Industry
- Biotechnology
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Advertisement
Common Questions About LGND.US
Market movers
Recent NASDAQ movers
Top 1-day gainers — updated from our Canadian movers feed.
| Ticker | Name | Price | 1D |
|---|---|---|---|
| BENF | Beneficient Class A Common Stock | $2.90 | +438.73% |
| JAGX | Jaguar Animal Health Inc | $8.91 | +233.71% |
| WHLR | Wheeler Real Estate Investment Trust, Inc. | $5.44 | +190.91% |
| VSA | TCTM Kids IT Education Inc. | $3.64 | +83.84% |
| ARTL | Artelo Biosciences Inc | $7.31 | +76.14% |
| BFRG | Bullfrog AI Holdings, Inc. Common Stock | $0.95 | +58.33% |
| VTGN | VistaGen Therapeutics Inc | $0.37 | +46.54% |
| IPDN | Professional Diversity Network Inc | $5.42 | +38.97% |
LGND.US news timeline
1 article covering LGND.US, most recent first
Latest